Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer

Journal of General Internal Medicine

Volumn 19, Issue 2, 2004, Pages 146-155

  Shavers, Vickie L ^a   Brown, Martin L ^a   Potosky, Arnold L ^a   Klabunde, Carrie N ^a   Davis, W W ^a   Moul, Judd W ^b   Fahey, Angela ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Conservative management; Ethnicity; Health disparities; Prostate cancer; Race; Watchful waiting

Indexed keywords

AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CAUCASIAN; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; ETHNIC DIFFERENCE; HISPANIC; HUMAN; LIFE EXPECTANCY; LOGISTIC REGRESSION ANALYSIS; MALE; PATIENT CARE; PROSTATE CANCER; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH;

AFRICAN AMERICANS; AGE FACTORS; AGED; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; LIFE EXPECTANCY; MALE; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 1642333176     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2004.30209.x     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts and Figures 2001. Atlanta, Ga: American Cancer Society; 2001.
2. American Cancer Society. Cancer Facts and Figures for African Americans. Atlanta, Ga: American Cancer Society; 2001.
3. Ries LAG, Eisner MP, Kosary CL, et al., eds. SEER Cancer Statistics Review 1973-99, National Cancer Institute. Bethesda, Md: http://seer.cancer.gov/ csr/1973-1999/2002.
4. Hoffman RM, Gilliland J, Eley W, et al. Racial and ethnic differences in advanced stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93:388-95.
5. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcomes Study. J Natl Cancer Inst; 2001;93:1864-71.
6. Klabunde C, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337-48.
7. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment of local and regional prostate cancer. Med Care. 1996;34:152-62.
8. Jones GW, Mettlin C, Murphy GP, et al. Patterns of care for carcinoma of the prostate gland. Results of a national survey of 1984 and 1990. J Am Coll Surg. 1995;180:545-54.
9. Fowler JE, Bigler SA, Bowman G, Kilambi NR. Race and cause-specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol. 2000;163:137-42.
10. Gilliland FD, Hunt WX, Key CR. Ethnic variation in prostate cancer survival in New Mexico. Cancer Epidemiol Biomarkers Prev. 1996;5:247-51.
11. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemlol. 2000;1511:409-16.
12. Morris CR, Snipes KP, Schlag R, Wright WE. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999;10:503-11.
13. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR. The National Cancer Data Base Report on race, age, and region variations In prostate cancer treatment. Cancer. 1997;80:1261-6.
14. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-57.
15. National Cancer Institute. Prostate Cancer (PDQ®) Treatment-Health Professionals. http://cancernet.nci.nih.gov.cgi. Last accessed: December 6, 2002.
16. National Comprehensive Cancer Network. The Complete Library of Practice Guidelines in Oncology. Rockledge, Pa: Rockledge: 2001.
17. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60:258-63.
18. Perron L, Moore L, Bairati I, Bernard P, Meyer F. PSA screening and prostate cancer mortality. Can Med Assoc J. 2002;166:586-91.
19. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-9.
20. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic clinical findings predict tumor extent nonpalpable (stage TIC) prostate cancer. JAMA. 1994;271:368-74.
21. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-90.
22. Vollmer RT, Egawa S, Kuwao S, Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate cancer. Cancer. 2002;94:1692-8.
23. Teloken C. Management of erectile dysfunction secondary to treatment for localized prostate cancer. Cancer Control. 2001; 6:540-5.
24. Grise P, Thurman S. Urinary incontinence following treatment of localized prostate cancer. Cancer Control. 2001;6:532-9.
25. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173-81.
26. Wilt TJ. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer. Semin Urol Oncol. 2002;20:10-7.
27. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst. 2000; 92:1582-92.
28. Yao S, Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 2002;94:958-9.
29. Tannock IF. Eradication of a disease: how we cured symptomless prostate cancer. Lancet. 2002;359:1341-2.
30. Vis AN. Does PSA screening reduce prostate cancer mortality? Can Med Assoc J. 2002;166:586-7.
31. Neal DE, Donovan JL. Prostate cancer: to screen or not to screen? Lancet Oncol. 2000;1:17-24.
32. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chimica Acta. 2002;315:71-97.
33. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare Data. Med Care. 2002;40 (suppl):IV-3-IV-18.
34. Fritz A, Ries L. The SEER Program Code Manual, 3rd edn. Cancer Statistics Branch, Surveillance Program, Division of Cancer Control and Population Sciences National Cancer Institute, January 1, 1998.
35. Anderson RN. Unites States Life Tables 1998 National Vital Statistics Reports. Vol. 48. No 18. Hyattsville. Md: National Center for Health Statistics; 2001.
36. Klabunde CN, Potosky AL, Legler JM, Warren J. Development of a co-morbidity measure using physician claims data. J Clin Epidemiol. 2000;53:1258-67.
37. SAS Institute Inc. SAS Version 9.0. Cary, NC.
38. The North-West Uro-Oncology Group. A Preliminary Report on a Patient-Preference Study to Compare Treatment Options in Early Prostate Cancer. Stockport, UK; BJU International; 2002;90:253-6.
39. Moul JW, Swsterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African American men. JAMA. 1995;274:1277-81.
40. Chapple A, Siebland S, Herxheimer A, McPherson HA, Shepperd S, Miller R. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int. 2002;90:257-64.
41. Diefenbach MA, Dorsey J, Uzzo RG, et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol. 2002;20:55-62.
42. Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer. 1998;83:320-30.
43. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-89.
44. McIntyre IG, Clarke RB, Anderson E, Clarke NW, George NJ. Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology. 2001;58:762-6.
45. Lee MM, Chang JS, Jacobs B, Wrensch MR. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health. 2002;92:1606-9.
46. Zietman A, Moughghan J, Owen J, Hanks G. The patterns of care survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiation Oncol Biol Phys. 2001;50:75-80.
47. Lai S, Lai H, Lamm S, Obek C, Krongrad A, Roos B. Radiation therapy in non-surgically-treated nonmetastatic prostate cancer: geographic and demographic variation. Urology. 2001;57:510-7.
48. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002:40:IV43-IV47.
49. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-Linked Data. Med Care. 2002;40(suppl):IV-49-IV-54.
50. Warren J, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(suppl): IV-55-IV-61.